A detailed history of Haven Capital Group, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Haven Capital Group, Inc. holds 59,143 shares of IOVA stock, worth $146,083. This represents 0.15% of its overall portfolio holdings.

Number of Shares
59,143
Previous 75,504 21.67%
Holding current value
$146,083
Previous $164 Million 1.83%
% of portfolio
0.15%
Previous 0.15%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 14, 2026

SELL
$1.81 - $2.65 $29,613 - $43,356
-16,361 Reduced 21.67%
59,143 $161 Million
Q3 2025

Nov 12, 2025

SELL
$1.7 - $3.97 $52,713 - $123,101
-31,008 Reduced 29.11%
75,504 $164 Million
Q2 2025

Aug 14, 2025

SELL
$1.66 - $3.61 $25,562 - $55,590
-15,399 Reduced 12.63%
106,512 $183 Million
Q1 2025

May 15, 2025

SELL
$3.33 - $7.79 $8,451 - $19,771
-2,538 Reduced 2.04%
121,911 $406 Million
Q4 2024

Feb 10, 2025

BUY
$7.17 - $12.28 $892,299 - $1.53 Million
124,449 New
124,449 $921 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $390M
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Haven Capital Group, Inc. Portfolio

Follow Haven Capital Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Haven Capital Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Haven Capital Group, Inc. with notifications on news.